VCM
VERA icon

Voleon Capital Management’s Vera Therapeutics VERA Stock Holding History

Voleon Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,847
Closed -$245K – 923
2025
Q4 		$245K Buy
+4,847
New +$172K 0.01% 696

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Voleon Capital Management's VERA Position: Q1 2026 in Review

Voleon Capital Management sold out of Vera Therapeutics (VERA) in Q1 2026, closing a stake of 4,847 shares — an estimated $245K sold.

Voleon Capital Management first reported a position in VERA in Q4 2025 and held it in 1 quarter. The position peaked at $245K in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Voleon Capital Management reported no remaining Vera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Voleon Capital Management sold 4,847 Vera Therapeutics shares in Q1 2026, an estimated $245K.
  • Voleon Capital Management first reported a position in Vera Therapeutics in Q4 2025 and held it in 1 quarter.
  • Voleon Capital Management's Vera Therapeutics position peaked at $245K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.